An open label, single-centric, non-randomized clinical study to evaluate the safety and efficacy of a new antimicrobial wound dressing (VELVERT) as an adjuvant therapy in patients having Necrotising soft-tissue infections (NSTI)/ fasciitis - Nil

开始日期2025-02-03

申办/合作机构

Datt Mediproducts Pvt Ltd.

CTRI/2024/07/070809 / Not yet recruiting临床4期

An interventional, open label, randomized, three arm comparative, Multi centric, post market clinical study to evaluate the safety and efficacy of medical devices used in adjuvant to the treatment of Venous leg ulcer. - Nil

开始日期2024-07-22

申办/合作机构

Datt Mediproducts Pvt Ltd.

CTRI/2024/06/068328 / Recruiting临床4期

A post marketing clinical follow-up study (PMCF) to evaluate safety and tolerability of VELNEZ as a nasal pack after nasal surgery.

开始日期2024-06-10

申办/合作机构

Datt Mediproducts Pvt Ltd.

100 项与 Datt Mediproducts Pvt Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Datt Mediproducts Pvt Ltd. 相关的专利（医药）

登录后查看更多信息

项与 Datt Mediproducts Pvt Ltd. 相关的文献（医药）

2021-02-01·Journal of Tissue Viability2区 · 医学

Chitosan and gelatin biopolymer supplemented with mesenchymal stem cells (Velgraft®) enhanced wound healing in goats (Capra hircus): Involvement of VEGF, TGF and CD31

2区 · 医学

Article

作者: Pandey, Siddharth ; Chaudhary, Gaurav ; Prabhu, Shyama N ; Shukla, Amit ; Garg, Satish Kumar ; Choudhury, Soumen ; Singh, Vandana

AIMCell-based therapy has emerged as promising strategy for chronic and impaired wounds treatment. Current research is focused on developing biomaterial systems that act as a niche for mesenchymal stem cells (MSCs) to promote wound healing through paracrine molecular cascading. This study was aimed to evaluate the wound healing potential of Velgraft, a ready-to-use biodegradable artificial skin substitute, on excision wound in goats.MATERIALS AND METHODSTwelve male goats were randomized divided in to three groups of four animals each. After infliction of surgical wound, Velgraft and Soframycin were applied on wounds of the animals of Groups II and III while Group I (sham operated) served as control. Wound diameters were measured at pre-defined time-points for determination of progressive wound healing up to 28 days. Skin sections were stained using Hematoxylin and eosin (H&E) for examining the histoarchitectural changes, Masson trichome staining for ascertaining collagen synthesis and immunohistochemistry for expression of CD31, VEGF and TGF-β1 proteins to determine post-treatment angiogenesis in the inflicted wounds.RESULTSVelgraft application appreciably enhanced wound closure by day 21 which was confirmed through restoration of the normal skin architecture as evident based on histopathological examination and characterized by complete regeneration of epidermal layers, collagen fibers, blood capillaries and hair follicular formation. Stimulation of angiogenesis markers was also observed at different time-points post-Velgraft application; which is suggestive of the improved angiogenesis and vasculogenesis.CONCLUSIONVelgraft facilitates wound healing by augmenting early wound closure, enhancing collagen synthesis and deposition, trichosis development and promoting revascularization and epidermal layers restoration.

2020-10-01·Molecular Biology Reports4区 · 生物学

Cartilage repair using stem cells & biomaterials: advancement from bench to bedside

4区 · 生物学

Review

作者: Kakkar, Anupama ; Saraswat, Sumit Kumar ; Srivastava, Supriya ; Singh, Aarti ; Pandey, Siddharth ; Nagar, Rakesh Kumar ; Khatri, Nitin ; Datt, Rajan ; Kumar, Mukesh ; Meena, Poonam

Osteoarthritis (OA) involves gradual destruction of articular cartilagemanifested by pain, stiffness of joints, and impaired movement especially in knees and hips. Non-vascularity of this tissue hinders its self-regenerative capacity and thus, the application of reparative or restorative modalities becomes imperative in OA treatment. In recent years, stem cell-based therapies have been explored as potential modalities for addressing OA complications. While mesenchymal stem cells (MSCs) hold immense promise, the recapitulation of native articular cartilage usingMSCs remains elusive. In this review, we have highlighted the chondrogenic potential of MSCs, factors guiding in vitro chondrogenic differentiation, biomaterials available for cartilage repair, their current market status, and the outcomes of major clinical trials. Our search on ClinicalTrials.gov using terms "stem cell" and "osteoarthritis" yielded 83 results. An analysis of the 29 trials that have been completed revealed differences in source of MSCs (bone marrow, adipose tissue, umbilical cord etc.), cell type (autologous or allogenic), and dose administered. Moreover, only 02 out of 29 studies have reported the use of matrix for cartilage repair. From future perspective, aconsensus on choice of cells, differentiation inducers, biomaterials, and clinical settings might pave a way for concocting robust strategies to improve the clinical applicability of biomimetic neocartilage constructs.

2018-12-01·Tissue Engineering and Regenerative Medicine3区 · 工程技术

Current Status of Stem Cell Treatment for Type I Diabetes Mellitus

3区 · 工程技术

Review

作者: Kakkar, Anupama ; Shrivastava, Pallavi ; Srivastava, Supriya ; Sorout, Ashima ; Pandey, Siddharth ; Datt, Rajan ; Saraswat, Sumit Kumar ; Tiwari, Mahak ; Meena, Poonam

BACKGROUNDDiabetes mellitus is a major health concern in current scenario which has been found to affect people of almost all ages. The disease has huge impact on global health; therefore, alternate methods apart from insulin injection are being explored to cure diabetes. Therefore, this review mainly focuses on the current status and therapeutic potential of stem cells mainly mesenchymal stem cells (MSCs) for Type 1 diabetes mellitus in preclinical animal models as well as humans.METHODSCurrent treatment for Type 1 diabetes mellitus mainly includes use of insulin which has its own limitations and also the underlying mechanism of diseases is still not explored. Therefore, alternate methods to cure diabetes are being explored. Stem cells are being investigated as an alternative therapy for treatment of various diseases including diabetes. Few preclinical studies have also been conducted using undifferentiated MSCs as well as in vitro MSCs differentiated into β islet cells.RESULTSThese stem cell transplant studies have highlighted the benefits of MSCs, which have shown promising results. Few human trials using stem cells have also affirmed the potential of these cells in alleviating the symptoms.CONCLUSIONStem cell transplantation may prove to be a safe and effective treatment for patients with Type 1 diabetes mellitus.

100 项与 Datt Mediproducts Pvt Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Datt Mediproducts Pvt Ltd. 相关的转化医学

登录后查看更多信息